Comprehensive genomic profiling (CGP) of tumors is an important aspect of determining therapy for individuals with advanced cancer. It is covered by Medicare for patients with advanced cancers seeking further cancer treatment, yet many commercial health insurance providers have limited coverage to small, targeted genetic panels.
This webinar will describe the difference between CGP and other types of genetic tests for cancer, identify how it helps patients and clinicians, and discuss therapies that rely on CGP as a diagnostic. Health insurance providers are often challenged with how to evaluate the clinical utility and clinical value of tests that include many genes, and this presentation will review Medicare and global models that can be utilized to evaluate CGP for advanced cancer.
Susan Hsiao, MD, PhD
Assistant Professor, Department of Pathology and Cell Biology
Columbia University Medical Center
Dr. Hsiao received her MD/PhD from New York University School of Medicine and trained in anatomic pathology and molecular genetic pathology at Columbia University Medical Center and University of Pittsburgh Medical Center. She is an Assistant Director in the Laboratory of Personalized Genomic Medicine and also serves as Director of Bioinformatics. Her interests include translational research in cancer genomics and utilization, coverage and reimbursement of molecular assays.
Kristine Bordenave, MD, FACP
KKBordenave Consulting Group, LLC
Dr. Bordenave spent nearly a decade as the Corporate Medical Director for Humana Inc. focusing on personalized medicine, laboratory services, and Medicare regulation. She has dedicated her career tailoring healthcare systems to ensure efficient high-quality resources for present and future generations. She now lends her expertise as a strategic consultant, having founded KKBordenave Consulting Group in January 2020.
She has more than 20 years of clinical and research experience and is a member of several organizations including American College of Physicians, AMA and The National Health Care Anti-Fraud Association. Dr. Bordenave has multiple publications and presentations related to chronic disease, business and clinical systems redesign and population genetics.